| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MAY 2016. Refer to TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | dapagliflozin (Forxiga®) | |
| Formulation | 5 mg and 10 mg film-coated tablet | |
| Reference number | 2745 | |
| Indication | Monotherapy for the treatment of adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance |
|
| Company | AstraZeneca UK Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 08/06/2015 | |
| Date of issue | 09/06/2015 | |
| NICE guidance | TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
|